Product category:
Laboratory and scientific databases
News Release from: IDBS | Subject: ActivityBase
Edited by the Laboratorytalk Editorial
Team on 04 November 2005
Spanish pharma firm to improve drug
discovery
J Uriach (Barcelona, Spain) plans to improve its current developmental focus on inflammatory diseases through the deployment of the ActivityBase software
IDBS reports the latest implementation of its flagship product, ActivityBase J Uriach (Barcelona, Spain) plans to improve its current developmental focus on inflammatory diseases through the deployment of the ActivityBase software
This article was originally published on Laboratorytalk on 18 Nov 2002 at 8.00am (UK)
Related stories
Biopharma data management on enterprise platform
Biopharmaceutical software for integrated biological and chemical data management in drug discovery research is now available for use with AIX, IBM's Unix operating system
Streamline QC in screening
Major enhancements in the leading drug discovery data management software facilitate workflows for biologists, compound handlers and system administrators
The company's 165-year heritage has resulted in many successful products, including the drug Triflusal (Disgren), currently one of the most prescribed antithrombotic agents in Spain.
Elena Carceller, head of medicinal chemistry for Uriach, said: "Our company has grown significantly during its long and prestigious history.
"This growth has presented us with new challenges regarding the day-to-day management of results.
"We needed a system that was scalable to our needs, but also one which was proven within the industry - which is why we chose IDBS".
IDBS first began discussing Uriach's requirements in 2003, when a clear requirement for one integrated platform to handle the biological, chemical and statistical data generated by the laboratory was established.
IDBS consultants determined how current information could be ported to the new ActivityBase environment, and how the new architecture could be applied to the current Uriach workflow.
This consultative approach prompted Robert Soliva, project manager for Uriach, to comment: "Rather than simply sell us a product, we were impressed with the professional approach IDBS adopted to ensure we had a system that was precisely suited to our requirements".
Neil Kipling, founder, chairman and CEO of IDBS said: "we have remained at the forefront of drug discovery data management for well over a decade now.
"It is deeply gratifying to know that major pharmaceutical companies continue to recognise the value our products deliver.
"IDBS views Spain as a significant emerging market for both biotech and pharmaceutical companies, and takes great pride in serving such a high percentage of those companies.".
• IDBS: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
